The pill, which utilizes the same semaglutide active ingredient found in the company’s blockbuster injections, arrives in Germany following regulatory approval from the European Commission in July. Pricing for the oral version is expected to mirror the existing Wegovy pen, with pharmacy retail costs ranging between €170 and €280 depending on the prescribed dosage. This strategic rollout follows earlier introductions in the United States, Britain, and the United Arab Emirates.

Novo Nordisk faces mounting pressure from U.S. competitor Eli Lilly, whose rival product, Foundayo, is currently under regulatory review across more than 40 markets. While Lilly’s drug has gained traction since its April launch in the U.S., Novo Nordisk claims its oral treatment currently commands 90% of the obesity pill market. Industry projections suggest that oral formulations could account for more than one-third of all GLP-1 drug usage by the end of the decade, making this European expansion a vital test for the company’s long-term market dominance.